Literature DB >> 9400932

Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?

P A Vasey, S B Kaye.   

Abstract

Mesh：

Substances：

Year:  1997        PMID： 9400932      PMCID： PMC2228166          DOI： 10.1038/bjc.1997.568

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  32 in total

1.  DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts.

Authors:  B C Giovanella; J S Stehlin; M E Wall; M C Wani; A W Nicholas; L F Liu; R Silber; M Potmesil
Journal:  Science       Date:  1989-11-24       Impact factor: 47.728

2.  Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.

Authors:  D Lefevre; J F Riou; J C Ahomadegbe; D Y Zhou; J Benard; G Riou
Journal:  Biochem Pharmacol       Date:  1991-06-15       Impact factor: 5.858

Review 3.  A model for tumor cell killing by topoisomerase poisons.

Authors:  H Zhang; P D'Arpa; L F Liu
Journal:  Cancer Cells       Date:  1990-01

4.  Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.

Authors:  K B Tan; M R Mattern; W K Eng; F L McCabe; R K Johnson
Journal:  J Natl Cancer Inst       Date:  1989-11-15       Impact factor: 13.506

5.  Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance.

Authors:  W T Beck
Journal:  J Natl Cancer Inst       Date:  1989-11-15       Impact factor: 13.506

6.  Combined modalities of resistance in etoposide-resistant human KB cell lines.

Authors:  P J Ferguson; M H Fisher; J Stephenson; D H Li; B S Zhou; Y C Cheng
Journal:  Cancer Res       Date:  1988-11-01       Impact factor: 12.701

Review 7.  DNA intercalating anti-tumour agents.

Authors:  B C Baguley
Journal:  Anticancer Drug Des       Date:  1991-02

8.  Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.

Authors:  R S Gupta; R Gupta; B Eng; R B Lock; W E Ross; R P Hertzberg; M J Caranfa; R K Johnson
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

9.  Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines.

Authors:  K Matsuo; K Kohno; H Takano; S Sato; A Kiue; M Kuwano
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

10.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.

Authors:  Y H Hsiang; L F Liu
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701
View more
  6 in total

1.  Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.

Authors:  Christian Dittrich; Veronique Dieras; Pierre Kerbrat; Cornelis Punt; Roberto Sorio; Francesco Caponigro; Xavier Paoletti; Christine de Balincourt; Denis Lacombe; Pierre Fumoleau
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

Review 2.  Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.

Authors:  Mateusz Kciuk; Beata Marciniak; Renata Kontek
Journal:  Int J Mol Sci       Date:  2020-07-12       Impact factor: 5.923

3.  Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan.

Authors:  Shinichiro Ryuge; Shi-Xu Jiang; Mayuko Wada; Ken Katono; Maiko Iwasaki; Akira Takakura; Sakiko Otani; Yuka Kimura; Tomoya Fukui; Masanori Yokoba; Masaru Kubota; Masato Katagiri; Kazusige Hayakawa; Noriyuki Masuda
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

4.  Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours.

Authors:  X Chen; A M Oza; Z Kusenda; Q-L Yi; D Kochman; M J Moore; A J Davis; L L Siu
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

5.  Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.

Authors:  I Sekine; Y Nishiwaki; R Kakinuma; K Kubota; F Hojo; T Matsumoto; H Ohmatsu; K Goto; T Kodama; K Eguchi; T Shinkai; T Tamura; Y Ohe; H Kunitoh; K Yoshimura; N Saijo
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

6.  Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.

Authors:  K Goto; I Sekine; Y Nishiwaki; R Kakinuma; K Kubota; T Matsumoto; H Ohmatsu; S Niho; T Kodama; T Shinkai; T Tamura; Y Ohe; H Kunitoh; N Yamamoto; H Nokihara; K Yoshida; T Sugiura; K Matsui; N Saijo
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.